Complex patients treated with zotarolimus‐eluting resolute and everolimus‐eluting xience V stents in the randomized TWENTE trial: Comparison of 2‐year clinical outcome

Abstract

Complex patients treated with Resolute ZES and Xience V EES showed similar safety and efficacy during 2-year follow-up. © 2014 Wiley Periodicals, Inc.

Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction

“…In agreement with those of the previous studies [12][13][14][15]17], the present study showed that R-ZES and EES were comparable in TLF in both MetS and Non-MetS patients, as were the individual components of TLF. Definite or probable ST rates were also comparable between the EES and R-ZES groups in both MetS and Non-MetS patients, in agreement with a recent meta-analysis [28].…”

“…Since the two randomized clinical trials with head-to-head comparison between EES and R-ZES showed that R-ZES was non-inferior to EES [12,13], similar results were reported in patients with complex clinical and angiographic characteristics in the study by Stefanini et al [14] and Senet al [15], and in diabetic patients in the study by Park et al [17].…”

“…In the previous studies, AMI patients were less than half of the studied patients (43.6% in the study by Stefanini et al,37.1% in the study by Sen et al,24.1% in the study by Park et al) [14,15,17]. In particular, AMI patients with MetS are contemporary important high-risk group, because MetS has greatly increased prevalence in AMI and has the potential to cause worse clinical outcomes, due to its properties [1][2][3][4][5][6][7][8].…”

“…Several studies including two randomized clinical trials, which directly compared EES and R-ZES, showed similar efficacy and safety of these 2 stents in all-comers and in complex patients. [12][13][14][15][16]. While a previous study suggested an interaction between stent type (EES vs. R-ZES) and diabetes [13], more recent study demonstrated that EES and R-ZES had similar clinical outcomes in patients with DM [17].…”

Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents

“…Furthermore, 2 trials reported similar outcomes for R-ZES and EES in patients with complex coronary lesions. 26,27 These aspects along with low rates of adverse events observed in both R-ZES and EES cohorts are reassuring in view of the widespread use of newgeneration DES in current clinical practice.…”